Valley National Advisers Inc Seagen Inc. Transaction History

Valley National Advisers Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $383 - $432	2 Added 3.23%	64 $14,000
Q2 2023 Jul 31, 2023	SELL	$187.64 - $206.25 $15,011 - $16,500	-80 Reduced 56.34%	62 $12,000
Q1 2023 Apr 26, 2023	SELL	$127.59 - $203.08 $3,700 - $5,889	-29 Reduced 16.96%	142 $29,000
Q4 2022 Jan 12, 2023	SELL	$117.37 - $139.17 $117 - $139	-1 Reduced 0.58%	171 $22,000
Q3 2022 Nov 08, 2022	BUY	$135.27 - $180.11 $6,492 - $8,645	48 Added 38.71%	172 $23,000

Q2 2022 Jul 15, 2022	BUY	$108.81 - $179.33 $4,896 - $8,069	45 Added 56.96%	124 $22,000
Q1 2022 May 06, 2022	SELL	$119.61 - $157.85 $2,272 - $2,999	-19 Reduced 19.39%	79 $11,000
Q4 2021 Feb 11, 2022	SELL	$142.57 - $190.86 $142 - $190	-1 Reduced 1.01%	98 $15,000
Q3 2021 Nov 10, 2021	BUY	$142.45 - $169.82 $2,564 - $3,056	18 Added 22.22%	99 $17,000
Q2 2021 Aug 02, 2021	BUY	$135.08 - $161.1 $3,512 - $4,188	26 Added 47.27%	81 $13,000
Q1 2021 May 07, 2021	BUY	$137.51 - $190.8 $7,563 - $10,494	55 New	55 $8,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Valley National Advisers Inc, based on Form 13F filings with the SEC.

Stay updated on Valley National Advisers Inc with notifications on news.